Zealand Pharma AS (LTS:0NZU)
kr 728 -0.5 (-0.07%) Market Cap: 51.36 Bil Enterprise Value: 43.28 Bil PE Ratio: 0 PB Ratio: 5.81 GF Score: 63/100

Zealand Pharma A/S Expands Its Peptide Platform with Acquisition of Encycle Therapeutics Inc Call Transcript

Oct 22, 2019 / 02:00PM GMT
Release Date Price: kr185.4 (+4.07%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to the Zealand Pharma Management Update Call. (Operator Instructions) I must advise you this conference is being recorded today. I would now like to hand the conference over to your first speaker today, Lani Morvan. Please go ahead.

Lani Pollworth Morvan;S;IR;Communications Officer
Zealand Pharma A

/-&

Thank you and thanks, everybody. Welcome to the special update with Zealand Pharma management to discuss our acquisition of Encycle Therapeutics. Leading today's call are Zealand's CEO, Emmanuel Dulac; and Rie Schultz Hansen is joining us for the first time as interim Chief Scientific Officer. Emmanuel will walk through the key aspects of our acquisition, and Rie will follow with insights into the emerging technology that makes this a strategic fit into Zealand's peptide platform. After the prepared remarks, we will open the call to take your questions.

For the Q&A, we will also be joined by Marino Garcia, Senior Vice President of Corporate

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot